Effect of fusion of radiomic, pathomic, and clinical biomarkers on multi-scale tumor biology and OS stratification in HNSCC receiving standard of care (SOC). Phase 2 trial of ozuriftamab vedotin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback